Free Trial

Oruka Therapeutics (ORKA) Stock Price, News & Analysis

Oruka Therapeutics logo
$10.26 -2.24 (-17.92%)
Closing price 04:00 PM Eastern
Extended Trading
$10.25 -0.01 (-0.10%)
As of 04:05 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Oruka Therapeutics Stock (NASDAQ:ORKA)

Key Stats

Today's Range
$9.86
$12.45
50-Day Range
$9.56
$14.29
52-Week Range
$9.44
$31.13
Volume
379,695 shs
Average Volume
215,818 shs
Market Capitalization
$384.14 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$39.86
Consensus Rating
Buy

Company Overview

Oruka Therapeutics, Inc. is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.

Remove Ads

Oruka Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
63rd Percentile Overall Score

ORKA MarketRank™: 

Oruka Therapeutics scored higher than 63% of companies evaluated by MarketBeat, and ranked 382nd out of 935 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Oruka Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.22, and is based on 7 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Oruka Therapeutics has only been the subject of 3 research reports in the past 90 days.

  • Read more about Oruka Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Oruka Therapeutics are expected to grow in the coming year, from ($3.41) to ($2.92) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Oruka Therapeutics is -1.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Oruka Therapeutics is -1.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Read more about Oruka Therapeutics' valuation and earnings.
  • Short Interest

    There is no current short interest data available for ORKA.
  • Dividend Yield

    Oruka Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Oruka Therapeutics does not have a long track record of dividend growth.

  • Short Interest

    There is no current short interest data available for ORKA.
  • News Sentiment

    Oruka Therapeutics has a news sentiment score of 1.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.82 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for Oruka Therapeutics this week, compared to 3 articles on an average week.
  • Insider Buying vs. Insider Selling

    In the past three months, Oruka Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $1,128,456.00 in company stock and sold $0.00 in company stock.

  • Percentage Held by Insiders

    22.67% of the stock of Oruka Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    56.44% of the stock of Oruka Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Oruka Therapeutics' insider trading history.
Receive ORKA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Oruka Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ORKA Stock News Headlines

While Markets Slide, These "Genesis Cog" Trades Are Up Double-Digits
While most investors are struggling in today's volatile market, a small group of traders are quietly booking consistent gains. Just last week, our Genesis Cog subscribers captured an 11.51% gain shorting JEF, another 8.57% on CAKE, and 4.78% on RJF—all while the broader indexes continued their downward trend.
Oruka Therapeutics announces preclinical data for ORKA-002
See More Headlines

ORKA Stock Analysis - Frequently Asked Questions

Oruka Therapeutics' stock was trading at $19.39 at the beginning of 2025. Since then, ORKA shares have decreased by 45.4% and is now trading at $10.5850.
View the best growth stocks for 2025 here
.

Oruka Therapeutics, Inc. (NASDAQ:ORKA) posted its quarterly earnings data on Thursday, March, 6th. The company reported ($0.49) EPS for the quarter, topping the consensus estimate of ($0.68) by $0.19.

Oruka Therapeutics' top institutional investors include FMR LLC (15.75%), Fairmount Funds Management LLC (9.63%), VR Adviser LLC (9.39%) and RTW Investments LP (5.56%).
View institutional ownership trends
.

Shares of ORKA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Oruka Therapeutics investors own include Astria Therapeutics (ATXS), Aldeyra Therapeutics (ALDX), Black Diamond Therapeutics (BDTX), Energy Transfer (ET), Heron Therapeutics (HRTX), Skye Bioscience (SKYE) and Skye Bioscience (SKYE).

Company Calendar

Last Earnings
3/06/2025
Today
3/31/2025
Next Earnings (Estimated)
4/24/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Diagnostic substances
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:ORKA
Previous Symbol
NASDAQ:ORKA
Employees
N/A
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$39.86
High Stock Price Target
$49.00
Low Stock Price Target
$20.00
Potential Upside/Downside
+276.5%
Consensus Rating
Buy
Rating Score (0-4)
3.22
Research Coverage
9 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-5,340,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Price / Book
N/A

Miscellaneous

Free Float
27,065,000
Market Cap
$396.31 million
Optionable
N/A
Beta
0.67
7 Energy Stocks to Buy and Hold Forever Cover

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

This page (NASDAQ:ORKA) was last updated on 3/31/2025 by MarketBeat.com Staff
From Our Partners